Our studies demonstrating that UCMD6 induces apoptosis of lung cancer cells in MOS, at least as efficiently as nivolumab, coupled with our previous data showing the ability of UMCD6 to suppress and control autoimmune diseases, fortify the pre-clinical rationale for the study of anti-CD6 as an effective and safer approach for cancer immunotherapy. This evidence concerns the gene CD6 and lung carcinoma.